

New hope for patients with serious diseases

Roche is committed to advancing science in order to find new treatment options for patients needing them the most.

Before being appointed as the General Manager of Roche Oy more than two years ago, Danish-born **Titus Gylvin**, MD, PhD, held several positions in the pharmaceutical field in both the United States and Europe. He has also worked intensively in China.

Gylvin reinforces and acknowledges his Nordic heritage: "We Nordics share a common set of values." It is evident that Gylvin feels strongly about ensuring that all patients have access to the best possible treatment, regardless from their socio-economic status.

Finding new treatments or cures for serious diseases is a passion for Gylvin as well as for others at Roche. "We are taking our leadership position in cancer treatments and treatments for other diseases very seriously and that is why we keep pushing the boundaries of science." Roche's strong focus on personalised healthcare has made it possible to offer patients treatment options that make positive outcomes more likely. "The development of these new types of highly tailored treatments is the result of years of work together with our partners across the globe"

COLLABORATING WITH FINNISH PARTNERS TOWARD CREATING BETTER TREATMENTS

Roche is a leading research-focused healthcare company headquartered in Switzerland whose strength is in combining pharmaceuticals and diagnostics. In the past eight consecutive years, Roche has been recognised as the most responsible healthcare company by Dow Jones Sustainability Index.

In 2015, Roche invested EUR 8.6 billion in research and product development. With its focus on R&D, the company is ranked first globally in healthcare sector R&D spending.*

Roche's R&D investments have led to significant pharmaceutical innovations, for example in the treatment of cancer, rheumatic diseases and immunological diseases. The company focuses on developing new medications for diseases where the need for new treatments is most urgent. The company is currently researching new treatments for example for neurological disorders, such as multiple sclerosis.

More than 100 years of innovation has resulted in 29 medicines developed by exclusively by Roche on the WHO Model Lists of Essential Medicines.

Roche Oy is a local organisation of approximately 90 people that has operated in Finland as an independent subsidiary since 1982, representing one of Finland's top companies in conducting clinical studies. Roche's studies are conducted through and



When meeting Roche Oy's General Manager **Titus Gylvin**, his strong passion for science and pharmaceutical innovations becomes clear: "We wish to rewrite medical text books by bringing new treatment innovations to the many patients in need!"

in partnership with all of Finland's university hospitals. In 2016, the company moved to closer research collaboration with the University of Helsinki, Helsinki University Hospital, TAYS Central Hospital, FinnMedi and Auria Biobank. Roche's success has reinforced its belief in Finland's potential for attracting even more research investments.

"With its biobanks and high level researchers, Finland has been recognised internationally as one of the best places to conduct pharmaceutical research. The collaboration agreements with our Finnish partners benefit patients in Finland and globally," Roche Oy's General Manager Titus Gylvin emphasises. ★

*Strategy& 2015 Global Innovation 1000 Analysis.